CR Bard Inc. announced July 25 the close of enrollment in its LEVANT 2
U.S. pivotal trial comparing its Moxy paclitaxel-coated percutaneous transluminal angioplasty balloon with standard balloon angioplasty for peripheral artery disease. Bard gained the Moxy device in January through its purchase...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?